Understanding Extended-Spectrum Beta-Lactamases and AmpC Beta-Lactamases
Author Information
Author(s): Kenneth S. Thomson
Primary Institution: Creighton University School of Medicine
Hypothesis
Clinical laboratories are not adequately equipped to detect extended-spectrum beta-lactamases (ESBLs) and plasmid-mediated AmpC beta-lactamases.
Conclusion
Clinical laboratories need better resources and training to effectively detect and report antibiotic resistance mechanisms.
Supporting Evidence
- ESBLs and AmpC beta-lactamases are often associated with multidrug resistance.
- Clinical laboratories are not fully aware of the importance of detecting these resistance mechanisms.
- Failure to detect these enzymes has led to therapeutic failures in patients.
Takeaway
Some bacteria can resist antibiotics, and labs need to be better at finding these bacteria to help doctors treat patients correctly.
Methodology
The article discusses the challenges and recommendations for detecting ESBLs and AmpC beta-lactamases in clinical laboratories.
Limitations
Many laboratories lack the resources and knowledge to detect these resistance mechanisms effectively.
Want to read the original?
Access the complete publication on the publisher's website